Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 outcomes and persistent symptoms in patients with hypertrophic cardiomyopathy: association with pre-existing cardiovascular magnetic resonance phenotype.

Heart (British Cardiac Society)·2026
Same author

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

JAMA·2026
Same author

Biobank-Scale Plasma Proteomics Identifies Novel Biomarkers in Hypertrophic Cardiomyopathy.

Circulation. Genomic and precision medicine·2026
Same author

Discovery of gene-alcohol interaction loci influencing blood pressure in 1.1 million individuals from multiple populations.

Research square·2026
Same author

Rational discovery of therapeutic PAK1 allosteric activators.

Cell·2026
Same author

Biallelic variants in RNU2-2 cause a remarkably frequent developmental and epileptic encephalopathy.

Nature genetics·2026

Related Experiment Video

Updated: May 6, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.

Sarah Wordsworth1, José Leal, Edward Blair

  • 1Health Economics Research Centre, University of Oxford, Old Road Campus, Oxford OX3 7LF, UK. sarah.wordsworth@dphpc.ox.ac.uk

European Heart Journal
|March 20, 2010
PubMed
Summary

Genetic screening for hypertrophic cardiomyopathy (HCM) is more cost-effective than clinical screening for preventing sudden cardiac death (SCD). This approach identifies more at-risk individuals, proving valuable for primary prevention.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.2K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K

Related Experiment Videos

Last Updated: May 6, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.3K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

1.2K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K

Area of Science:

  • Cardiology
  • Genetics
  • Health Economics

Background:

  • Hypertrophic cardiomyopathy (HCM) is the leading genetic heart condition and a primary cause of sudden cardiac death (SCD) in young individuals.
  • Screening family members is crucial for identifying at-risk individuals and enabling preventative strategies.
  • Current screening often relies on clinical assessments, but the effectiveness of genetic approaches is under investigation.

Purpose of the Study:

  • To evaluate the cost-effectiveness of cascade genetic screening compared to cascade clinical screening for hypertrophic cardiomyopathy (HCM).
  • To determine the most economically viable strategy for identifying individuals at risk of SCD due to HCM.

Main Methods:

  • An economic decision model was utilized to compare cascade screening strategies.
  • The model contrasted genetic testing approaches with traditional clinical assessment methods.
  • Key economic metrics, such as the incremental cost per life year saved, were calculated.

Main Results:

  • Cascade genetic screening demonstrated a favorable incremental cost per life year saved (€14,397) compared to cascade clinical screening.
  • Genetic diagnostic strategies were found to be more cost-effective than relying solely on clinical tests.
  • While initial costs for molecular genetic testing were slightly higher, its superior effectiveness in identifying at-risk individuals justified the investment.

Conclusions:

  • Integrating molecular genetic information into the diagnosis and management of HCM represents a cost-effective strategy.
  • This approach is highly effective for the primary prevention of sudden cardiac death (SCD) in families affected by HCM.
  • Genetic screening offers a superior and economically sound method for managing hypertrophic cardiomyopathy.